📉 Resilient Trader Trade Idea: The Cannabis Rescheduling Catalyst in Glass House Brands (GLASF)

Sponsored by

Is Your Retirement Plan Built to Last?

Most people saving for retirement have a number in mind. Fewer have a plan for turning that number into actual income.

The Definitive Guide to Retirement Income walks you through the questions that matter: what things will cost, where the money comes from, and how to keep your portfolio aligned with your long-term goals.

If you have $1,000,000 or more saved, download your free guide and start building a retirement income plan that holds up.

Download your free guide.

Resilient Trader is where smart traders come for vetted ideas.

A rare Saturday edition…………………Every week, we cut through the noise and surface opportunities that institutions are already eyeing - but with strategies tailored for retail traders. Today’s setup? A California cannabis powerhouse that just survived a brutal 2025 and is perfectly positioned for the biggest regulatory shift in U.S. cannabis history.

We’ll cover:

• Why Glass House Brands (GLASF) is a Buy at current levels.

• How the DOJ's move to Schedule III completely changes the game and brings cannabis into the FDA's medical approval regime.

• Why the stock has the chance to make a major breakout here and hit a 3-year high despite Congressional headwinds.

🔍 Trade Thesis: GLASF Is Ready for a Major Breakout on Rescheduling News

Glass House Brands (GLASF) has been an incredible turnaround story. After surviving devastating ICE raids in July 2025 that gutted its workforce and slashed production by 60%, the company has rebuilt its operations, overhauled its labor practices, and is now targeting 30% revenue growth in 2026.

But the real story broke this week.

Behind the scenes:

🚨 Schedule III is Here: Acting Attorney General Todd Blanche officially signed an order reclassifying state-licensed medical marijuana from Schedule I (federally illegal) to Schedule III (prescription-required controlled substance). This fulfills President Trump's December 2025 executive order.

📉 280E Tax Relief: This is the holy grail for cannabis operators. Moving to Schedule III stops the accrual of unpaid taxes and allows companies to deduct normal operating expenses. In 2025, the industry paid an estimated $2.24 billion in excess federal taxes. That burden is now gone, immediately improving P&L statements across the board.

🏥 The New FDA Medical Framework: The federal government is moving to bring marijuana into the FDA's medical approval regime. This means standardizing manufacturing, labeling, dispensing protocols, and establishing strict prescription frameworks. This is distinct from the current state-level recreational dispensary model. While this adds regulatory hurdles, large, vertically integrated operators like Glass House-which already maintains high cultivation standards-are best positioned to adapt and thrive under FDA oversight compared to smaller, undercapitalized competitors.

🏛️ Congressional Headwinds: While the executive branch is moving fast, legislative reform remains stalled. The President separately called on Congress to reform CBD legislation, but Congressional support is highly limited. Key figures like Speaker Mike Johnson and Senator Tom Cotton have voiced strong opposition to loosening restrictions. However, because rescheduling is an administrative action by the DOJ/DEA, it bypasses the immediate need for Congressional approval, allowing the 280E tax relief to take effect regardless of the gridlock on Capitol Hill.

🧾 Banking & Uplisting: Schedule III opens the door to traditional banking access, better credit terms, and paves the way for major exchange uplisting. The DOJ also confirmed a new administrative hearing for June 29, 2026, to evaluate broader changes to the cannabis scheduling framework.

📊 The Fundamentals Are Rebounding Strongly

Glass House took a hit in 2025, but the 2026 outlook is incredibly bullish.

Let's break it down:

💰 Revenue: 2025 revenue came in at $181.98 million (down 9.4% YoY due to the ICE raids). However, 2026 guidance projects $235 to $245 million, implying nearly 30% growth at the midpoint.

📉 Profit Margins: Gross margin dipped to 42.29% in 2025, but management forecasts a return to 48% in 2026. Adjusted EBITDA is projected in the high $40 million range.

📦 Balance Sheet & Cash Flow: The company ended 2025 with $23.4 million in cash. With 280E tax relief now a reality, free cash flow will see a massive positive swing. Management expects year-end 2026 cash to exceed $50 million.

🛠️ Retail Expansion: Glass House just announced a massive joint venture with Vireo Growth, combining their California dispensary networks to create a 23-store retail powerhouse.

🧮 Cost Advantage: Glass House remains the lowest-cost producer in California, projecting roughly 1 million pounds of biomass production in 2026 at an average cost of $100 per pound.

📐 Valuation and Competitor Comparison

GLASF is priced attractively relative to its growth potential and asset base:

⚖️ Market Cap vs. Assets: Trading at a market cap of $852 million, the company holds $234.67 million in Property, Plant & Equipment (massive greenhouse real estate).

🏷️ Revenue Comparison: While senior operators like Curaleaf ($331M/qtr) and Green Thumb ($311M/qtr) dominate nationally, Glass House ($38.9M/qtr) dominates the massive California market.

📈 Analyst Ratings: Wall Street agrees. The average analyst rating is a Buy, with an average 1-year price target of $10.75, and a high forecast of $12.65.

🧭 Technicals Agree: A Breakout is Imminent

This stock has the chance to make a major breakout here and will hit a 3-year high.

✅ Strong Momentum: Price is trading well above all key moving averages (50-day at $8.14, 100-day at $8.30, 200-day at $7.67).

✅ Barchart Opinion: An overwhelming 88% BUY signal across 13 technical indicators.

✅ Volume Surge: The stock surged over 15% yesterday on massive volume (>1.1 million shares) ahead of the rescheduling announcement.

🏷️ Current price: $9.85

🎯 Targets: $12.75 (initial), $16.65 (intermediate) $24.00 (long-term)

🛡️ Investment Thesis & SWOT Analysis

⚡ Strengths: Lowest-cost cultivator in California; vertically integrated; massive greenhouse infrastructure; well-positioned to meet new FDA manufacturing standards.

⚠️ Weaknesses: Single-state exposure (California); 2025 revenue dip due to labor disruptions; high debt relative to cash.

💡 Opportunities: Schedule III rescheduling (280E tax relief); banking access; uplisting potential; Vireo Growth retail JV; hemp expansion.

🛑 Threats: New costs associated with FDA compliance (labeling, dispensing protocols); strong Congressional opposition (Sen. Cotton, Speaker Johnson) stalling broader CBD/cannabis legislative reform; illicit market competition.

⭕ The Bottom Line: For value and growth investors alike, the intrinsic value of GLASF is set to skyrocket as 280E tax relief flows directly to the bottom line. While the shift to an FDA medical approval regime and Congressional gridlock present long-term complexities, the immediate regulatory catalyst is here, and the technical support a sustained run.

💥 Trade of the Week: Long Equity Position

We’re taking a direct long equity position to capitalize on the rescheduling momentum. Note: This stock does not currently have listed options, so we are playing the common stock outright.

🟢 Trade Setup

• Buy $GLASF ( ▲ 3.2% )  at $9.85

🛑 Risk Management Tip

Set a trailing stop-loss at $8.15 (just below the 50-day moving average) to protect capital while allowing room for upside volatility as the news cycle digests the DOJ announcement and the FDA framework implications.

🚀 Catalysts on the Horizon

Keep your eyes on:

1. June 29, 2026 - The new DEA administrative hearing begins regarding the broader rescheduling of marijuana.

2. FDA Guidance Rollout - Watch for new regulations on manufacturing standards and prescription frameworks, which could act as a moat for large operators like Glass House.

3. May Earnings (Q1 2026) - Look for updated guidance reflecting the exact financial impact of 280E removal.

4. Vireo Growth JV Integration - Watch for retail revenue synergies in the second half of the year.

🧠 Final Thoughts

GLASF is a classic case of a company that took its lumps, restructured, and is now perfectly positioned for a macro tailwind.

From the end of the 280E tax burden to a massive retail expansion and an overwhelmingly bullish technical setup-this trade has all the ingredients for a profitable long position. Even with the shift toward stricter FDA medical frameworks and Congressional opposition on broader reform, the immediate financial benefits of Schedule III are undeniable.

✅ Buy GLASF at $9.85

We'll be watching this one closely.

Want more trade ideas like this - plus weekly options plays and breakdowns?

👉 Join the Paid Resilient Trader Newsletter

For more in-depth trading strategies and market insights, upgrade to the paid version of our newsletter.

Our paid newsletter gives you:

• Weekly stock + options trade ideas

  • Market commentary and macro insights

    • Easy-to-follow setups with defined risk

Stay Liquid, my friends and Happy New Year!
- The Resilient Trader